TaiGen Biopharmaceuticals

Company 4157.TWO

Last mentioned: Mar 6, 2026

Timeline

  1. Phase I Initiation

    First human subject enrolled and dosed in the Phase I clinical trial.

  2. Out-Licensing Deal

    TaiGen Biopharmaceuticals acquires rights for clinical development and commercialization.

  3. Candidate Discovery

    Insilico Medicine identifies ISM4808 using generative AI models.

Stories mentioning TaiGen Biopharmaceuticals 1

clinical-trial Bullish

Insilico and TaiGen Advance AI-Derived CKD Anemia Candidate to Phase I

Insilico Medicine and TaiGen Biopharmaceuticals have achieved a major clinical milestone with the first human dosing of ISM4808, an AI-discovered small molecule for Chronic Kidney Disease (CKD) anemia. This Phase I trial marks a critical validation point for Insilico’s Pharma.AI platform and triggers a milestone payment from TaiGen.

3 sources